Comparative Pharmacology
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE versus TALWIN NX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE versus TALWIN NX.
BUPRENORPHINE HYDROCHLORIDE vs TALWIN NX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors, producing analgesia and reducing opioid withdrawal symptoms.
Pentazocine is a mixed agonist-antagonist opioid analgesic that acts as an agonist at kappa opioid receptors and as an antagonist or partial agonist at mu opioid receptors. Naloxone is added to prevent intravenous abuse but has no oral bioavailability.
Sublingual: 8-16 mg once daily. Transdermal: 5-20 mcg/hour applied every 7 days. Injectable: 0.3 mg IM/IV every 6-8 hours as needed.
1 tablet (pentazocine 50 mg/naloxone 0.5 mg) orally every 3-4 hours as needed for pain; maximum 12 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 20-73 hours (mean ~37 hours); prolonged half-life supports sublingual dosing every 24-48 hours in opioid dependence.
2-3 hours (terminal) for pentazocine; naloxone half-life 1-1.5 hours. Clinically, duration limited by pentazocine's shorter half-life.
Primarily fecal (70%) via biliary excretion; renal excretion accounts for 20-30% as unchanged drug and metabolites (mainly norbuprenorphine glucuronide).
Renal: ~60% as unchanged drug and glucuronide conjugates. Biliary/fecal: ~20% as metabolites. Total: 80% eliminated within 72 hours.
Category C
Category C
Opioid Partial Agonist
Opioid Partial Agonist/Antagonist